Appoints Dr Leila Alland and Dr Jeremy Barton as strategic advisor and Interim CMO
Jubilant Therapeutics announced the appointments of Dr Leila Alland, to its Board of Directors and Dr Jeremy Barton, as Strategic Advisor and Interim Chief Medical Officer.
“The Jubilant Therapeutics team is making great strides in developing precision oncology therapeutics and I am honoured to be joining their Board and supporting them in advancing their exciting pipeline into the clinic,” said Dr Alland.
Dr Alland currently serves as Chief Medical Officer of PMV Pharmaceuticals where she is responsible for leading the company’s clinical-stage precision anticancer therapies. Previously, she served as Chief Medical Officer at Affimed and Tarveda Therapeutics and held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough.
Dr Alland completed her fellowship in pediatric haematology-oncology at the New York Hospital and Memorial Sloan-Kettering Cancer Center and served as Assistant Professor of Pediatrics at Albert Einstein College of Medicine, where she was awarded the James S. McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer and blood disorders.
“I am excited to be working with Jubilant Therapeutics and contributing to advancing their pipeline of novel therapeutics to address unmet needs in patients with cancer and autoimmune diseases,” said Barton.
Dr Barton brings to Jubilant Therapeutics over 29 years of experience across all phases of oncology drug development from major pharmaceutical companies in Switzerland, the UK and the US. He currently works as a consultant advising biotech companies on strategic oncology drug development.
Previously, Dr Barton served as Chief Medical Officer at Biogen Idec, eFFECTOR Therapeutics, and Mirati Therapeutics. He served as the Head of early oncology development at Pfizer for where he oversaw the transition of all oncology compounds from research to IND and then to proof-of-concept studies. Dr Barton is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of Faculty of Pharmaceutical Medicine. He earned his Master’s in Physiology from Oxford University and his MD degree at University College Hospital Medical School in London.
“It is a pleasure to welcome Dr Alland to the Jubilant Therapeutics board and Dr Barton to the team,” said Hari S Bhartia, Chairman, Jubilant Therapeutics Inc. “They join at an exciting time as we progress towards the clinic and I look forward to their engagement and support in guiding our objectives.”
“Dr Alland and Dr Barton’s combined experience in strategic oncology drug development will help propel the company towards our goal to bring innovative small molecule modulators to patients with cancer,” said Syed Kazmi, President and CEO, Jubilant Therapeutics.
